Physician profile
Saif Fatteh
NPI 1093001299
$9,456.44
in general payments reported to CMS, 2019-2025
30 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $916 · 2021: $1,286 · 2022: $1,643 · 2023: $1,636 · 2024: $1,739 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,073 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,073.25 |
| Education | $206.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,589.29 | 2020-2025 | Tremfya |
| Abbvie INC. | $1,030.93 | 2021-2025 | |
| Amgen INC. | $954.52 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $801.51 | 2019-2025 | |
| Ucb, INC. | $767.30 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $671.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $588.68 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $567.59 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $529.23 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.92 | 2022-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $278.13 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $238.61 | 2023-2024 | Vtama |
| Leo Pharma INC. | $185.89 | 2022-2025 | Adbry |
| Organon LLC | $175.59 | 2022-2025 | Vtama, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $127.11 | 2024-2025 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $122.89 | 2021-2025 | Nemluvio |
| Dermira, INC. | $71.50 | 2020 | |
| Celgene Corporation | $56.53 | 2019 | |
| Mylan Institutional INC. | $50.49 | 2023 | Hulio |
| Arcutis Biotherapeutics, INC. | $47.52 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $45.07 | 2021-2022 | |
| Genentech USA, INC. | $43.38 | 2024-2025 | Xolair |
| Allergan, INC. | $38.75 | 2020-2021 | |
| Incyte Corporation | $24.58 | 2025 | Opzelura |
| Biofrontera INC. | $23.54 | 2020-2022 | |
| Novo Nordisk INC | $21.73 | 2024 | Ozempic, Rybelsus |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.18 | 2020 | |
| Merck Sharp & Dohme LLC | $13.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Almirall LLC | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saif Fatteh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.